Literature DB >> 30603278

Chronic hyperglycemia may attenuate the serum-uric-acid-lowering effect of low-dose febuxostat in Japanese patients with type 2 diabetes mellitus.

Yukihiro Bando1, Hitomi Toyama1, Hideo Kanehara1, Azusa Hisada1, Kazuhiro Okafuji1, Daisyu Toya1, Nobuyoshi Tanaka1.   

Abstract

AIMS: This study investigated the independent predictors of the serum uric acid (sUA)-lowering effect of low-dose febuxostat, a novel xanthine oxidase inhibitor, in Japanese patients with type 2 diabetes mellitus (T2DM).
MATERIALS AND METHODS: Data of 130 T2DM patients who had been taking febuxostat 10 mg once daily for elevated sUA (≥7 mg/dl) for at least 12 weeks were retrieved from medical records. Spearman's rank correlation coefficients were calculated to determine the correlations between sets of two independent continuous variables. Multiple stepwise linear regression analysis was used to determine independent predictors of the percent change of sUA levels after 12 weeks of febuxostat treatment (%ΔsUA).
RESULTS: Among all patients, %ΔsUA was significantly correlated with age (ρ = 0.192, P = 0.030) and mean glycated hemoglobin (HbA1c) level (ρ = -0.186, P = 0.036). Multiple stepwise linear regression analysis of all patients revealed that major independent factors contributing to %ΔsUA were mean HbA1c (β = -3.14, P = 0.022) and mean glycated albumin (β = -0.743, P = 0.013) levels.
CONCLUSIONS: High HbA1c and glycated albumin levels significantly attenuated the sUA-lowering effect of low-dose febuxostat in Japanese patients with T2DM. Further detailed analysis using a larger population is warranted to confirm these findings.

Entities:  

Keywords:  Febuxostat; Glycated albumin; Glycated hemoglobin; Serum uric acid; Type 2 diabetes

Year:  2016        PMID: 30603278      PMCID: PMC6224986          DOI: 10.1007/s13340-015-0251-x

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  28 in total

Review 1.  [Uric acid metabolism and insulin resistance in type 2 diabetes].

Authors:  Taro Wasada; Masako Iwatani
Journal:  Nihon Rinsho       Date:  2002-08

2.  An enzymatic method for the measurement of glycated albumin in biological samples.

Authors:  Takuji Kouzuma; Tomomi Usami; Masaru Yamakoshi; Mamoru Takahashi; Shigeyuki Imamura
Journal:  Clin Chim Acta       Date:  2002-10       Impact factor: 3.786

3.  Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol.

Authors:  Marí-Carmen Desco; Miguel Asensi; Rafael Márquez; José Martínez-Valls; Máximo Vento; Federico V Pallardó; Juan Sastre; José Viña
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

4.  Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting.

Authors:  Aylin Altan Riedel; Mike Nelson; Katrine Wallace; Nancy Joseph-Ridge; Michele Cleary; Adel G Fam
Journal:  J Clin Rheumatol       Date:  2004-12       Impact factor: 3.517

5.  Glycaemic control in relation to xanthine oxidase and antioxidant indices in Malaysian Type 2 diabetes patients.

Authors:  U R Kuppusamy; M Indran; P Rokiah
Journal:  Diabet Med       Date:  2005-10       Impact factor: 4.359

6.  Japanese standard reference material for JDS Lot 2 haemoglobin A1c. I: Comparison of Japan Diabetes Society-assigned values to those obtained by the Japanese and USA domestic standardization programmes and by the International Federation of Clinical Chemistry reference laboratories.

Authors:  Makoto Tominaga; Hideichi Makino; Gen Yoshino; Katsuhiko Kuwa; Izumi Takei; Yukuko Aono; Tadao Hoshino; Masao Umemoto; Akira Shimatsu; Tokio Sanke; Masamichi Kuwashima; Tomohiko Taminato; Junko Ono
Journal:  Ann Clin Biochem       Date:  2005-01       Impact factor: 2.057

7.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension.

Authors:  R Butler; A D Morris; J J Belch; A Hill; A D Struthers
Journal:  Hypertension       Date:  2000-03       Impact factor: 10.190

Review 8.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

9.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.

Authors:  Josef Coresh; Brad C Astor; Tom Greene; Garabed Eknoyan; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

Review 10.  Oxidant stress in the vasculature.

Authors:  M Maytin; J Leopold; J Loscalzo
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.